Pemetrexed: 6 agencies, 2005–2023
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
On the same population the two systems disagree outright: PBAC (Australia) recorded recommended for “Mesothelioma Locally advanced or metastatic non-small cell lung cancer”, while SMC (Scotland) recorded not recommended for “Non-small cell lung cancer”.
The file has been open for more than a decade: 17.8 years separate the first record, 24 Oct 2005 at AWMSG (Wales), from the most recent, 2023 at PBAC (Australia).
NICE (England) changed its position: not recommended on 22 Aug 2007, recommended by 23 Jun 2010, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for pemetrexed, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The programme is broad: 12 distinct indication wordings are recorded for pemetrexed by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 27 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess pemetrexed, on 24 Oct 2005; CIPM (Spain) did not open a file until 2 Feb 2023 — an unusually long tail of 17.3 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 14 years in total.
5 of the 6 agencies here assessed pemetrexed more than once, HAS (France) most often at 12 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for pemetrexed.
The full ledger for pemetrexed reads 18 recommended, 2 not recommended, 2 restricted and 2 deferred to NICE, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2023 | Mesothelioma Locally advanced or metastatic non-small cell lung cancer | Recommended | source |
| CIPM (Spain) | 2 Feb 2023 | Indicaciones terapéuticas autorizadas y financiadas: Mesotelioma pleural maligno ALIMTA en combinación con cisplatino, e… | excluded from SNS provision · art. 92 e | source |
| HAS (France) | 6 Jan 2021 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| AWMSG (Wales) | 8 Mar 2012 | Monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predom… | superseded (non-submission) | source |
| SMC (Scotland) | 11 Oct 2010 | Non-small cell lung cancer | not recommended | source |
22 further decisions for pemetrexed, across 5 agencies, are not shown here. They link to 18 further source documents.
Related molecules
- ramucirumab — divergent outcome (recommended vs not recommended) on a shared indication
- mobocertinib — divergent outcome (recommended vs withdrawn) on a shared indication
- sotorasib — divergent outcome (recommended vs not recommended) on a shared indication
- tarlatamab — divergent outcome (recommended vs not recommended) on a shared indication
- azacitidine — same ATC class L01B — Antineoplastics
- gemcitabine — same ATC class L01B — Antineoplastics
Coverage: 27 decisions for pemetrexed from 6 agencies, 2005 to 2023. Data to 7 Sep 2026. ATC class L01B — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.